BeOne Medicines (ONC) Depreciation and Depletion (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Depreciation and Depletion data on file, last reported at $39.4 million in Q1 2026.

• On a quarterly basis, Depreciation and Depletion rose 24.58% year-over-year to $39.4 million in Q1 2026; TTM through Mar 2026 was $139.4 million, a 20.1% decrease from a year earlier, with the FY2025 full-year figure at $131.6 million, down 21.16% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $39.4 million, up from $34.4 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for ONC reached as high as $70.0 million in Q3 2024 and fell as low as $14.5 million in Q2 2022.
• Historically, Depreciation and Depletion has averaged $28.3 million across 5 years, with a median of $23.8 million in 2024.
• Across the five-year window, Depreciation and Depletion jumped 263.93% in 2024 and plunged 48.98% in 2025, its largest moves.
• Year by year, Depreciation and Depletion stood at $17.0 million in 2022, then gained by 22.38% to $20.9 million in 2023, then soared by 135.1% to $49.0 million in 2024, then slipped by 29.83% to $34.4 million in 2025, then rose by 14.43% to $39.4 million in 2026.
• Per Business Quant data, the three most recent Depreciation and Depletion figures were $39.4 million in Q1 2026, $34.4 million in Q4 2025, and $35.7 million in Q3 2025.